RecruitingNCT04544774

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy: An Academic Multicentre Clinical Study


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

200 participants

Start Date

Jul 16, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy. The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years. This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AIT and NAPT for people with local allergic rhinitis, perennial allergic rhinitis, and other related conditions. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAIT

AIT for airborn allergens (SCIT/SLIT)

DIAGNOSTIC_TESTNAPT

NAPT test with airborn allergens ( HDM, Threes, Grasses)


Locations(2)

UZ Leuven

Leuven, Vlaam Brabant, Belgium

AZ Sint-Jan

Bruges, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04544774


Related Trials